Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

NCT03007732 PHASE2 COMPLETED Results posted

This is a non-comparative open-label multicenter Phase 2 clinical trial combining stereotactic body radiation therapy (SBRT) and pembrolizumab with or without intratumoral SD-101 in participants with newly diagnosed hormone-naive oligometastatic prostate cancer.

Details

Lead sponsor	David Oh
Phase	PHASE2
Status	COMPLETED
Enrolment	23
Start date	Wed May 17 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Mar 31 2025 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Prostatic Neoplasms

Interventions

• Pembrolizumab
• SD-101
• Leuprolide acetate
• Abiraterone Acetate
• Prednisone
• Stereotactic Body Radiation Therapy

Countries

United States